



**ESGO**  
European Society of  
Gynaecological Oncology


Management of Uterine cancer  
during COVID-19 Pandemic

ESGO COVID-19 update

April 15, 2020  
18.00 CEST

WEBINAR WEBINAR WEBINAR WEBINAR

# ESGO



## Annual Update 2020




### A REVIEW

### OF THE EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY PROJECTS AND INITIATIVES IN 2020



**ESGO**  
European Society of  
Gynaecological Oncology





# Table of contents

Introduction	4
Coronavirus response	6
State of the Art Conference 2020	8
ESGO Webinars & Courses	10
ESGO eAcademy	14
The updated ESGO Curriculum	16
Individual accreditation	18
ESGO Training Centre certifications	19
ESGO Advanced Ovarian Cancer certifications	20
International Journal of Gynecological Cancer	23
Guidelines	24
ENGOT	26
ENYGO	28
ENGAGe	32
World Gynaecological Oncology Day	36
Prevention activities	38
Cooperations	39
Membership	40
ESGO Elected Officials	42
Office	43
What's to come in 2021	44

## ESGO vision

Best prevention  
and treatment  
of gynaecological cancers.

## ESGO mission

ESGO strives to improve the health  
and well-being of women  
with gynaecological cancers  
through prevention, research,  
excellence in care and education.

# Introduction

*Dear ESGO friends and colleagues,*

We hope that the year 2021 brings you and your loved ones peace and joy. We are pleased to start the new year by presenting you with the results of a new project: this document. The ESGO Annual Update 2020 is a report that introduces and celebrates the many projects our hardworking council members, committee volunteers, and staff undertook in the last year.

The ESGO Council started 2020 by creating a solid strategic plan that outlines the next five years for our Society and cements our goals and objectives while giving us a framework for future growth. Of course, back in January last year, we didn't know that one of the toughest recent years for ESGO—and for the world—was beginning!

The year 2020 will always be connected in the history books to the COVID-19 outbreak and subsequent pandemic. Over the last months, we have seen our membership overcome the front lines of the pandemic in order to bring the absolute best care to their patients with gynaecological cancers. We are proud that our Society has been able to continue our aim of improving education, prevention, and care through it all. Moreover, we are proud of having been able to proactively maintain the connections in our community and respond to the scientific and organisational need for information about the treatment and care of patients, starting from the very first weeks of the pandemic. More about **our ongoing COVID-19 efforts** can be found **on page 6**.

Thanks to the tireless efforts of our volunteers, our elected officials, and our staff, we managed to bring an uninterrupted slate of benefits to our members and sponsors throughout this unusual year. The crisis brought new opportunities in the digitisation of education. Our **Education Committee**, in particular, worked overtime to fill the gaps in our education schedule once it became clear that in-person events were not in the interest of public health. Instead, they quickly turned to organising online content and now produce a webinar every week, which afterwards are available to view in the ESGO eAcademy. **See page 10** to learn more about our Educational projects and **page 14** for the ESGO eAcademy and its many offerings, including CME-accredited courses!

Another project to highlight from the Education Committee is our newly updated ESGO Curriculum, which took effect January 1, 2021. In 2020, 3 training centres were accredited; we also ran our first ever re-accreditation as a tele-visit, which worked so well this new work mode will now be a permanent part of our process.



Prof. Philippe Morice  
ESGO President



Jonathan Ledermann  
ESGO Vice President

Our commitment to creating pan-European standards for gynaecological oncology training and patient care continues as well, despite the restrictions on movement caused by the pandemic. Read about our **Guidelines Committee** and the numerous projects developed in collaboration with European sister societies, including recommendations and quality indicators. We discovered how efficient working virtually can be for our geographically dispersed experts, and all projects in 2020 were easily developed via teleconferences or at hybrid meetings.

In December, our **Congress Committee** pulled off a fantastic State of the Art Conference—a virtual meeting, rather than an in-person one, but educational to the attendees and valuable to the science, nonetheless. According to our panellists and speakers, this was the most interactive ESGO conference ever. **See page 8**. In the meantime, they have also been hard at work preparing the **23<sup>rd</sup> ESGO European Congress**, which will be a hybrid meeting with in-person sessions in Prague, Czech Republic. Public health situation allowing, we anticipate ESGO 2021 will be a dynamic, rewarding ESGO Congress just like you're used to, but with new, digital elements.

Our **young doctors network, ENYGO**, has been hard at work on a number of exciting activities and opportunities—you can read about them **on page 28**—while our **patient advocacy network ENGAGE** has raised awareness for gynaecological cancers worldwide through their World GO Day events and their cooperation with the World Health Organization for cervical cancer elimination. Read about ENGAGE **on page 32** and our clinical trial network ENGOT **on page 26**.

And there is still more to say! The new **Prevention Committee** made great progress in developing numerous projects in the field of prevention, where ESGO would like to be particularly active (**page 38**). The **Scientific Committee** focused on webinars to spread research and new data, and the **Quality Assurance & Certification Committee** worked quite proactively and certified ten new hospitals in Ovarian Cancer surgery!

We are pleased with how the gynaecological oncology community has risen to overcome the obstacles and continue toward progress throughout 2020. Thank you for your interest in and support of our 2020 activities. We hope to see you at our online and in-person events and discussions in 2021 as well.



**Philippe Morice, France**  
**ESGO President**



**Jonathan Ledermann, UK**  
**ESGO Vice President**



**The European Voice of Gynaecological Oncology**

# Coronavirus response

In February and March, 2020, it became apparent that the SARS-Cov-2 virus was an ongoing public health concern in Europe and worldwide; the World Health Organization declared it a pandemic on March 11. By that time, our members were already feeling the impact of the rapidly spreading virus on their medical centres, patients, and communities.

ESGO quickly launched a series of webinars to help our members share front-line experiences in patient care during the COVID-19 pandemic. Our first webinar took place in March and featured experts from Spain and Italy who shared their experiences from the front line of the European response to the pandemic.



## **How to manage ovarian cancer during the COVID-19 pandemic, March 31**

**Moderators:** Jonathan Ledermann & Max Lanner

**Speakers:** Luis Chiva, Spain; Anna Fagotti, Italy; Antonio González Martín, Spain; Sandro Pignata, Italy



## **How to manage uterine cancer during the COVID-19 pandemic, April 15**

**Moderators:** Jonathan Ledermann & Max Lanner

**Speakers:** Jalid Sehouli, Germany; Christian Marth, Austria; Nadeem Abu-Rustum, USA; Nicoletta Colombo, Italy; Carien Creutzberg, Netherlands



## **How to manage cervical cancer during the COVID-19 pandemic, May 12**

**Moderators:** David Cibula & Max Lanner

**Speakers:** Murat Gultekin, Turkey; Pedro Ramirez, USA; Mary McCormack, UK; Domenica Lorusso, Italy

**All 3 COVID-19 webinars  
were offered to the community  
free of charge.**

**They are available to view  
on the ESGO eAcademy.**

Webinar

March 31  
18.00 CET

- » Jonathan Ledermann (UK)
- » Anna Fagotti (IT)
- » Antonio González (SP)
- » Luis Chiva (SP)
- » Sandro Pignata (IT)



### Additional ESGO network projects addressing the pandemic:

- A webinar produced by ESGO and its network ENGAGe on gynaecological patient care before and after the pandemic, and including **patient perspectives** from a survey conducted with ESGO clinical trial network ENGOT, was held September 8.
- ENGAGe is translating an informational **brochure to guide gynaecological cancer** patients during the COVID-19 pandemic, which should be available for distribution in 2021.
- ENGOT produced **recommendations for clinical trials** during the pandemic.

ESGO swiftly moved its in-person classes and events to online formats, where possible. This included changing the ESGO 2020 State of the Art Conference planned for Copenhagen in June to a fully online, highly interactive virtual meeting in December.

ESGO also dramatically expanded its webinar offerings and ESGO eAcademy content to satisfy the suddenly increasing demand for online learning. By the end of 2020, new webinars, including the popular Meet the Surgeon series were being produced weekly. **See page 10 to learn more about our webinar content.**

---

The European Federation for Colposcopy (EFC) and the European Society of Gynaecological Oncology (ESGO) released joint advice on the management of cervical cancer screening and prevention during the ongoing COVID-19 pandemic. Cancer prevention and early diagnosis may be postponed, with the aim of balancing between patient care, local COVID-19 trends, and health systems' capacity. Read more: <https://pubmed.ncbi.nlm.nih.gov/32487685/>

---

# State of the Art Conference 2020

## Conference Chairs: Mansoor Raza Mirza & Christina Fotopoulou



ESGO's first-ever virtual meeting was also our largest-ever conference! **More than 800 speakers and delegates** attended the ESGO 2020 Virtual Meeting, which was held on the Multilearning platform from December 14–16 with the theme A Decade of Advances in Gynaecological Cancer Care. Originally scheduled as an in-person meeting in June in Copenhagen, Denmark, the home

of Conference Co-chair Mansoor Raza Mirza, the public health situation resulting from the pandemic soon made it clear changes would be made. Acting swiftly and with the intent of preserving the ambitious scientific programme, Mirza, fellow Co-Chair Christina Fotopoulou, and the Congress Committee rescheduled the event for December.

As the year wore on and it became clear that it was increasingly unsafe for delegates and presenters to attend any meetings in person, the plan changed to a hybrid event, and, finally, an on-line-only event. The result was three days of back-to-back online sessions that included panel discussions and plenty of audience interaction, as well as industry symposia and online e-poster viewing. Perhaps because of the online format, this year the conference drew attendees from 68 countries—and every inhabited continent!

## ESGO 2020 by the numbers

Registered attendees **836**...  
...coming from **68** countries  
Speakers **29**  
Abstracts **298**  
Late-breaking abstracts **38**



## Conference Highlights



The change in format did nothing to diminish the strong scientific programme with an emphasis on interactive panels. The first day of the meeting focused on cervical cancer, the second on ovarian cancer and the third on endometrial cancer. Highlights included:

 The **ESGO-ESTRO-ESP Endometrial Cancer Guidelines** were presented for the first time publicly by Nicole Concin.

 A presentation on the **ESGO-ESMO Ovarian Cancer Guidelines**, by Nicoletta Colombo.

 Part II of the **Major Advances in Gynaecological Cancer** discussion, chaired by Luis Chiva and Mansoor Raza Mirza, which was a continuation of the Part I offered as a webinar in June (see page 10). This session featured the following topics:

- **The ABRAX trial and what next?** by David Cibula
- **Relapse surgery in Ovarian cancer-improving outcome of our patients** by Andreas du Bois
- **Role of immunotherapy in gynaecological malignancies** by Antonio González Martín
- **Advances in targeted therapy in gynaecological cancers** by Jonathan Ledermann



The conference committee has been hard at work all year on a great programme.

See [congress.esgo.org](http://congress.esgo.org) for more information.

**CHAIR:** *Jonathan Ledermann*, Congress Committee Chair,  
ESGO 2021 Programme Committee Chair



**MEMBERS:**

*David Cibula*, ESGO 2021 Congress President;

*Nicole Concin*, Past Programme Chair;

*Nadeem Abu-Rustum; Sandro Pignata*, ENGOT representative;

*Andrei Pletnev*, ENYGO representative



# ESGO Webinars & Courses



## Training & Education Committee

**Chair:** Anna Fagotti



## Courses Working Group

Cagatay Taskiran, surgical

Jonathan Ledermann, non surgical

Nicolò Bizzarri, ENYGO

Jan Persson, robotics

Education is a key part of the ESGO mission and strategy, with regular **theoretical and practical courses** held throughout the year that often sell out due to high demand. In 2020, two in-person courses were held; the rest were postponed for the safety of our faculty and the attendees. Regular in-person courses will be resumed in mid-2021, if the public health situation allows. The ESGO Education Committee, faculty, and staff quickly turned to creating **webinars so that our members could continue their education at home**. By the end of 2020, ESGO is producing nearly one webinar per week and plans to continue this schedule in 2021.



## COURSES

- **Advanced Course on Multidisciplinary Management of Cervical Cancer**

(14 CME credits; in collaboration with ESTRO) **15. 1. 2020 - 17. 1. 2020 | Paris, France**

*\*This course was designed to accommodate multidisciplinary teams of gynaecological oncologists and radiation oncologists*

**Chairs:** Philippe Morice, Remi A Nout, Elzbieta van der Steen-Banasik

**Faculty:** Mary McCormack, Cyrus Chargari, David Cibula, Alexandros Rodolakis, Christina Fotopoulou, Fabio Landoni, Murat Gultekin, Christine Haie-Meder, Corinne Balleyguier, Sebastien Gouy

- **Advanced Course in Fertility-Sparing Management of Gynaecological Cancers**

(14 CME credits), **27. 2. 2020 - 29. 2. 2020 | Hamburg, Germany**, at the European Surgical Institute

*\*This course addressed the very special aspects that affect fertility and fertility preservation in young patients with gynaecological cancers*

**Chairs:** Philippe Morice, Christina Fotopoulou

**Faculty:** Richard Smith, Jalid Sehouli, Christhardt Köhler, Tom Bourne, Alexandros Rodolakis, Philipp Harter, David Cibula



## WEBINARS



### MEET THE SURGEON

ESGO's popular Meet the Surgeon webinars shine a spotlight on leading surgeons working today. The webinars include a 30-minute presentation of the featured surgeon's technique and approach to a particular topic followed by a 30-minute discussion and Q&A. All webinars are available after broadcast on the ESGO eAcademy. As of November 2020, participants who join a Meet the Surgeon webinar live are eligible for 1 CME credit.

*Meet the Surgeon Webinars are moderated by Luis Chiva and Maximilian Lanner and have a rotating cast of panellists.*

- **Colorectal resection by Gwenaël Ferron, May 28**  
Panellists: Anna Fagotti; Denis Querleu; and Cagatay Taskiran
- **Left upper abdomen debulking by Santiago Domingo, June 30**  
Panellists: Artem Stepanyan; Denis Querleu; and Cagatay Taskiran
- **Management of bulky paraaortic and suprarenal lymph nodes by Cagatay Taskiran, July 23**  
Panellists: Artem Stepanyan; Denis Querleu; and Anna Fagotti
- **Everything you need to know about radical vaginal surgery for cervical cancer by Denis Querleu, September 24**  
Panellists: Artem Stepanyan; Cagatay Taskiran; and Anna Fagotti
- **Cytoreductive techniques in advanced ovarian cancer by Christina Fotopoulou, October 22**  
Panellists: Artem Stepanyan; Cagatay Taskiran; and Denis Querleu
- **Laparoscopic Extended Pelvic Lymphadenectomy Internal Iliac Vessel System and Sciatic Nerve Anatomy by Artem Stepanyan, November 19**  
Panellists: Cagatay Taskiran; Denis Querleu; and Santiago Domingo
- **Multidisciplinary management of liver metastases in ovarian cancer by Anna Fagotti, December 10**  
Panellists: Artem Stepanyan; Denis Querleu; Cagatay Taskiran; and Giovanni Aletti

## **SPECIAL INTEREST WEBINARS**

---

Additional webinars were created this year to suit special interests.

- **Major Advances in Gynaecological Cancers – Part I, June 25**

**Moderators:** Mansoor Raza Mirza, Nicole Concin

**Discussion:**

- **Is secondary cytoreductive surgery in ovarian cancer a new standard of care:** Andreas du Bois
  - **The PARP journey:** Jonathan Ledermann
  - **Immune therapy in gynaecological cancers:** Nicoletta Colombo
  - **The role of sentinel lymph-node biopsy:** Jan Persson
  - **Endometrial cancer in the era of targeted therapy:** Alexandra Leary
  - **Are we over-rating intermediate-risk cervical cancer?:** David Cibula
- Part II of this discussion was held on Dec. 16 at ESGO 2020.

- **The new ESGO Curriculum, a new training paradigm, November 3**

A webinar to present the new ESGO Curriculum was held, featuring Curriculum author Rene Verheijen (Netherlands); ESGO Education Committee Chair Anna Fagotti (Italy); Curriculum co-authors Rasiah Bharathan (UK), Aleksandra Strojna (Poland), and Kamil Zalewski (Poland); and moderated by Max Lanner (Austria).

- **See Updated Curriculum on page 16**
- **Webinar series on patient management during the COVID-19 pandemic – see page 6**

# WEBINARS

---

## Live Multidisciplinary Tumour Boards

---

A joint project between ESGO and its young doctors' network ENYGO, the live multidisciplinary tumour boards webinars showcase an interactive discussion on key topics. Each tumour board discussion is hosted by various presenters from diverse European centres. Each centre offers two cases with diagnostic considerations that are discussed during the meeting; each webinar ends with a 20-minute lecture on a relevant topic. All past webinars are available on the ESGO eAcademy.

- **Cervical Cancer, June 10**

Minsk: N.N. Alexandrov National Cancer Centre of Belarus

**Panellists:** Alexander Shushkevich, Andrei Pletnev, Elzbieta van der Steen Banasik, Zoia Razumova

- **Ovarian Cancer, September 21**

The Challenges of a BRCA-mutated Ovarian Cancer Patient

**With:** Anna Fagotti | Gemelli Hospital, Rome, Italy

**Panellists:** Nicolò Bizzarri, Nicoletta Colombo, Christina Fotopoulou, Denis Querleu, Natalia Rodriguez, Alexander Shushkevich, Gian Franco Zannoni

- **Endometrial Cancer, October 16**

Debate on the management of endometrial cancer after surgery in the sentinel node era

**With:** Dr Alessandro Buda | San Gerardo Hospital, University of Milano-Bicocca, Italy

**Panellists:** Nicoletta Colombo, Tommaso Grassi, Marta Jaconi, Piotr Lepka, Alexander Shushkevich, Elzbieta van der Steen-Banasik, René Verheijen, Benedetta Zambetti

- **Vulvar Cancer, November 27**

Management of vulvar cancer patients

**With:** Ate van der Zee | University Medical Centre Groningen, Netherlands

**Panellists:** Harry Hollema, Maaïke Oonk, Thijs Roelovsen, Alexander Shushkevich, Charalampos Theofanakis, Elzbieta van der Steen-Banasik, René Verheijen, Kamil Zalewski

**Webinars created by ENYGO are listed on page 28.**

**Webinars created by ENGAGe are listed on page 32.**

# ESGO eAcademy

## Training & Education Committee

**Chair:** Anna Fagotti

**eAcademy Editor-in Chief:**

Luis Chiva



### eLearning Working Group (ESGO eAcademy)

**Denis Querleu**, eAcademy editor-in-chief until October 2020 – lead

**Luis Chiva**, eAcademy editor-in-chief after October 2020

**Cagatay Taskiran**, video library

**Artem Stepanyan**, video library

**Agnieszka Rychlik**, eAcademy fellow

**Maxmilian Lanner**, ENYGO

**Jan Persson**, robotic section

## CME stars

Distance learning allowed ESGO members to keep up on their CME credits even while social distancing. This year, more than **30 members** from more than **16 countries** completed all of the CME-accredited courses on the ESGO eAcademy. **Well done!** The eAcademy contained videos worth a potential **38 CME-credits** as of December, 2020, with more planned to be added regularly in the future.

## The ESGO Gynaecological Oncology eAcademy is the official knowledge portal of ESGO.

Since it was founded in 2013, the eAcademy has grown from a list of a few video and publication uploads to a voluminous e-learning portal containing publications, webinars, and more than 210 surgical videos from more than 700 contributors. In 2020, ESGO relaunched the eAcademy site to improve the user experience. The new responsive design scales seamlessly across different devices from a desktop, tablet or mobile device, making it easier for users to view the eAcademy collections.



## Among other categories, ESGO members can access:

- **CME COURSES.** By the end of 2020, the eAcademy boasted 7 courses worth CME credits. More will be added in 2021!
- **SURGICAL VIDEO COLLECTION.** The base of the eAcademy, this collection offers videos on a variety of surgery topics.
- **WEBINARS.** In 2020, ESGO initiated a robust programme of webinars, with new content published almost every week. Recordings of most these webinars are freely available for members to view on demand.
- **FREE CONTENT.** While most of the resources on the eAcademy are available only to ESGO members, some webinars with wider public interest, such as the webinars on patient care during the COVID-19 pandemic, are available for everyone. ESGO non-members can access these items after making a free account on the site.
- **RUSSIAN COLLECTION.** An initiative of Council member Artem Stepanyan (Armenia), the eAcademy hosts a growing collection of videos produced in the Russian language.



**3** the minimum number of new webinars uploaded to the eAcademy each month

**25** topics to browse

**700+** International contributors

**2,500+** items in the eAcademy as of December 2020

## Distinguished LECTURE SERIES 2020

We were proud to add the following videos to the eAcademy Distinguished Lecture series this year:

- Dirk Timmerman. *IOTA*
- Karl Tamussino. *The history of radical HT*
- Sean Kehoe. *FIGO classification - ongoing challenges*
- Marlene Kranawetter. *Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery*
- Pedro Ramirez. *Inspiring leader interview*
- Annette Hasenburg. *Sexuality in cancer survivors*
- Christina Fotopoulou. *Webinar*

## Most popular TOPICS in 2020

- Surgical Techniques videos, top viewed contributor: **David Cibula, Czech Republic,**
- High-Grade Serous Ovarian Cancer videos, top viewed contributor: **Murat Gultekin, Turkey**
- General Care videos, top viewed contributor: **Jalid Sehoul, Germany**

## Most popular VIDEOS in 2020

- Nerve-sparing radical hysterectomy Muallem Technique by **Mustafa Zelal Muallem, Germany**
- Hudson procedure in 10 steps by **Gwenaël Ferron, France**
- Nerve-sparing surgery by **Berta Diaz Feijoo, Spain**

# The updated ESGO Curriculum



## Committee



### ESGO

**Chair: René Verheijen**, Netherlands;  
**Annamaria Ferrero**, Italy; **Jordi Ponce**, Spain;  
**Dimitrios Haidopoulos**, Greece;  
**Ranjit Manchanda**, UK

### ENYGO

**Kamil Zalewski**, Poland; **Rasih Bharathan**, UK;  
**Angela Melo**, Italy; **Gloria Cordeiro Vidal**, Spain

### EBCOG

**Annalisa Tancredi**, Italy

The first revision of the ESGO Curriculum was an ambitious, extensive project chaired by René Verheijen. The Curriculum sets out in detail **the European standards and expectations for training specialists in gynaecological oncology and the criteria used to award the ESGO Diploma**. Regular updates to the Curriculum allow it to reflect best practices in the field and in educational techniques.

## METHOD

- **Issues** were identified through literature & guidelines
- **Delphi questionnaire** of questions that cover most pertinent issues
- Survey sent in **2 rounds** to all trainers, trainees and council and the Heads of the gynae-onc departments of ESGO-accredited centres
- All answers with **>60% consensus** were accepted
- **Inconclusive issues** were discussed and decided by CRC
- **Draft of curriculum** based on survey discussed in Athens
- **Amendments** to be made + **portfolio** drafted



## HIGHLIGHTS

---

- The Curriculum is now consensus-based
- It adheres to the principles of competence-based assessments
- It follows and is partly integrated with the EBCOG PACT curriculum for general training in obstetrics and gynaecology.
- A real-time portfolio is now required, for which an online logbook will be provided.
- Successful completion of the curriculum and a passing mark on the ESGO theoretical examination are mandatory requirements for obtaining the ESGO certification

**The revised  
ESGO Curriculum  
took effect January 1, 2021.**

**[Read it here!](#)**

One of the requirements of the updated ESGO Curriculum for earning an ESGO Diploma is **successful completion of the ESGO Exam.**

---

The next Exam will take place at the **ESGO 2021** Congress, in **Prague**, Czech Republic.

---

**[Learn more!](#)**

# Individual accreditation



Fellows interested in the gynae-oncology subspecialty can follow the Curriculum (see page 16) at ESGO Training Centres. Following 2–3 years of full-time (or equivalent) training, their completed documentation (as of 2020, an eLogbook) is approved by the Working Group of Fellowships and Observerships of the Education Committee.

***In 2020, 13 trainees from 9 countries earned their ESGO Diplomas.  
CONGRATULATIONS!***

- **Martina Aida Angeles Fite, MD**

Trained at the Department of Surgical Oncology,  
Institut Universitaire du Cancer de Toulouse – Oncopole, France

- **Ariel Gustavo Glickman, MD**

Trained at the GYNECOLOGIC ONCOLOGY UNIT,  
BARCELONA CLÍNIC HOSPITAL

- **Claire Thompson, MD**

Trained at the Department of Gynaecological Oncology,  
St James's Hospital, Dublin, Ireland

- **Ibon Jaunarena Marin, MD**

Trained at the Department of Obstetrics & Gynaecology,  
Donostia University Hospital, Donostia, Spain

- **Olesya Solheim, MD**

Trained at the Department of Gynaecological Oncology,  
the Norwegian Radiumhospital, Oslo University Hospital

- **Natascha de Lange, MD**

Trained at the Department of Gynaecological Oncology,  
University Medical Centre Groningen, The Netherlands

- **Agnieszka Rychlik, MD**

Trained at the Institut Bergonie,  
Department of Surgery, Bordeaux, France

- **Henrica Maria Johanna Werner, MD**

Trained at the Department of Gynaecology and Obstetrics,  
Haukeland University Hospital, Bergen, Norway

- **İlker Çakır, MD**

Trained at the Department of Gynaecologic Oncology,  
University of Health Sciences Tepecik Education and Research Hospital, Bornova/İzmir, Turkey

- **Behzat Can, MD**

Department of Gynaecologic Oncology,  
University of Health Sciences Tepecik Education and Research Hospital, Bornova/İzmir, Turkey

- **Tine Henrichsen Schnack, MD**

Trained in the Copenhagen University Hospital,  
Rigshospitalet, Copenhagen, Denmark

- **Utku Akgör, MD**

Trained in the Hacettepe University Faculty of Medicine,  
Department of Gynaecological, Oncology, Ankara, Turkey

- **Volkan Karataşlı, MD**

Trained in the University of Health Sciences Tepecik Education and Research Hospital  
Department of Gynaecologic Oncology, Bornova, İzmir, Turkey

# ESGO Training Centre accreditations

## Working Group of Fellowships and Observerships of the Education Committee

This group reviews and advises on applications for accreditation as a training centre.



**Chair:** René Verheijen

Anna Fagotti, Maja Pakiz, Annamaria Ferrero,  
Ignacio Zapardiel, Luis Chiva, Andrei Pletnev,  
Nicolò Bizzarri



*The ESGO accreditation visit to Ege University Hospital, Bornova/Izmir, Turkey, in February 2020.*

*Visitors: ESGO Council member Ignacio Zapardiel (Spain) and ENYGO Executive Group member Zoia Razumova (Sweden)]*

**As part of ESGO's aim to harmonise and standardise training in gynaecological oncology in Europe, ESGO has set a subspecialty training programme and requirements for centres that will provide ESGO-accredited training.**

Centres seeking training centre accreditation or re-accreditation usually receive an on-site visit. Due to the COVID-19 pandemic, some new accreditations were paused until an on-site visit can be made, and some of the re-certification interviews were performed over teleconference.



## Training Centres accredited in 2020

- **Ankara City Hospital**, Maternity Hospital, Division of Gynaecologic Oncology, Ankara, Turkey
- **Ege University Faculty of Medicine**, Department of Obstetrics & Gynaecology Division of Gynaecologic Oncology, Erzene Turkey
- **Florence Nightingale Hospital of the Kaiserswerther Diakonie**, Teaching hospital of the University of Düsseldorf, Germany
- **Tel-Aviv Sourasky Medical Centre**, Lis Maternity Hospital, Department of Obstetrics & Gynaecology, Tel Aviv-Yafo, Israel
- **The Odense University Hospital / University of Southern Denmark**, Dept. of Obstetrics and Gynaecology, Odense, Denmark
- **The Gynaecology Oncology Unit**, 2nd Department of Obstetrics and Gynaecology, A.U.TH, Ippokration General Hospital, Thessaloniki, Greece

# ESGO Advanced Ovarian Cancer certifications

## Quality Assurance and Certifications committee



**Chair:** Luis Chiva

Elzbieta van der Steen-Banasik,  
Pawel Knapp,  
Ignacio Zapardiel

ESGO advances the standards of quality of care by certifying cancer centres in the management of ovarian cancer, based on defined quality indicators. Similar certification is being prepared for cervical cancer, based on quality indicators in surgery and radiation oncology.

**To date, 55 centres across Europe have received the ESGO Advanced ovarian cancer surgery certification, out of these, 18 were certified as Centres of Excellence. In 2020, 12 European centres were certified for Ovarian Cancer Surgery and 2 Centres of Excellence**



## Ovarian Cancer Surgery Centres certified in 2020

- **Florence-Nightingale-Hospital of University of Dusseldorf**, Germany (Centre of Excellence)
- **Gynaecological Oncology Surgical Unit, Istituto Nazionale dei Tumori**, Milan, Italy (Centre of Excellence)
- **St. Mary's Hospital, Manchester University Foundation Trust**, UK, Manchester UK
- **Royal Derby Hospital UK, Derby Gynaecological Cancer Centre**, UK. Derby, UK
- **Hopital Lyon Sud, Chirurgie Cancerologique Gynecologique**, France
- **The Christie NHS FT, Gynaecological Oncology Surgery, Surgical Directorate**, Manchester, UK
- **Department of Medicine and Surgery, University of Milan Bicocca, UOC of Gynaecology**, Italy
- **Gdynia Oncology Centre, Pomeranian Hospital, Department of Gynaecological Oncology**, Poland
- **Catharina hospital/Catharina Cancer Institute, Department of Gynaecological Oncology**, Eindhoven, Netherlands
- **Clinic of Obstetrics and Gynaecology , University of Milan Bicocca**, Ospedale S. Gerardo Monza, Italy
- **La Paz University Hospital, Gynaecologic Oncology Unit**, Madrid Spain
- **Mater Misericordiae University Hospital, Dublin, Ireland, Department of Gynaecological Oncology**, Dublin, Ireland
- **Nairi Medical Centre, Department of Gynaecological Oncology**, Yerevan, Armenia
- **University Hospital of Bialystok, University Oncology Centre of Bialystok**, Poland
- **General University Hospital of Valencia**, Valencia Spain

# International Journal of Gynecological Cancer



**ESGO IJGC CHAIR:** Jonathan Ledermann

**COMMITTEE:** Philippe Morice, Nicole Concin, David Cibula

## **JOURNAL EDITORS**


**Editor-in-chief:** Pedro T Ramirez

**Associate editors:** Anna Fagotti, Michael Frumovitz, Antonio González Martín, Anuja Jhingran, Rene Pareja

**Video editor:** Luis Chiva

**Social media editor:** Ane Gerda Zahl Eriksson

**Managing editor:** Lindsey Struckmeyer



## ***The International Journal of Gynecological Cancer***

is the official journal of ESGO and a joint project between ESGO and the International Gynecological Cancer Society (IGCS). ESGO members count a free subscription to the journal as one of their membership benefits.

In 2020, the IJGC grew its outreach and online presence and also increased its impact factor to 2.09 (as of June 2020). It published monthly in 2020, as well as producing weekly podcasts that further explored the contents of the journal. Regular features in the journal include video articles and the 'corners of the world' section that highlights the geographic diversity of the contributors and points of view presented.

Every month, the Journal editors and the author(s) of the relevant lead article discuss the topic presented in a journal club on Twitter with the hashtag #IJGCclub and the public are invited to participate. Polls before the event help shape the discussion. Each event draws dozens of participants from around the world.

## **EDITORIAL BOARD FELLOWS**

IJGC ESGO & IGCS Fellows. ENYGO members can apply to join the IJGC editorial team as IJGC fellows.

### **2020 ESGO-IJGC Fellows**

- Gabrielle van Ramshorst • Louise Wan • Zoia Razumova
- Joanna Kacperczyk-Bartnik • Aleksandra Strojna • Martina Angelès Fité

### **In 2020, the Journal**

- Launched an active IJGC Fellow Twitter account
- Launched a Fellows' Choice podcast which reviews the monthly issue in English and selected other languages, including Spanish and Mandarin

### **Editors' Choice Award 2020**

David Cibula for **European Society of Gynaecological Oncology (ESGO) Quality indicators for surgical treatment of cervical cancer**

### **Most Downloaded Paper Award 2020**

Gloria Salvo for **Updates and management algorithm for neuroendocrine tumors of the uterine cervix**

#IJGCclub

Introducing discussant @lchiv4

Dr. Chiva is the Director of the Department of OB/GYN at Clínica Universidad de Navarra. He is also the Video Editor of #IJGC, Editor-in-Chief of E-academy and Chair of Quality Assurance & Certifications Committee at @ESGO\_society

**#IJGCclub – DISCUSSANT DR. LUIS CHIVA**



We are joined by Dr. Luis Chiva to discuss the SUCCOR study and his article, "SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer," which is the Lead Article in the September 2020 issue of IJGC.

Dr. Chiva is the Director of the Department of Obstetrics and Gynecology at Clínica Universidad de Navarra. He is also the Video Editor of IJGC, Editor-in-Chief of E-academy and Chair of Quality Assurance & Certifications Committee at European Society of Gynecological Oncology.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

5:00 PM · Sep 18, 2020 · Hootsuite Inc.

Welcome to November #IJGCclub w @annafagottimD to discuss SCORPION trial: "Randomized trial of PDS vs NACT for advanced epithelial #OvarianCancer" Please introduce yourselves, remember #IJGCclub w tweets & questions. GO! 🌟

@ESGO\_society @IGCSociety @IJGcfellows @pedroramirezMD

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | BMJ Journals

**Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)**

Fagotti Anna, Ferrandina Gabriella, Vizzelli Giuseppe, Pasciuto Tina, Fanfani Francesco, Gallotta Valerio, Margariti Pasquale, Chiantera Vito, Costantini Barbara, Gueli Alletti Salvatore, Cosentino Francesco, Scambia Giovanni

Eligible patients: +18 to 75 yrs, presumed FIGO stage III or IV, ECOG PS 0-2

Randomized: +Clinical evaluation, +Thorax and Abdominal CT scan

S-LPS: +Pile-score 8-12, +Epithelial Ovarian Cancer at FS

1:1 Random: +PDS (Arm A), +NACT (Arm B)

Primary outcome: +Surgical complications, +PFS

Characteristic	Post-operative major complications	
	Arm A PDS (n=84)	Arm B NACT (n=74)
Major events	39 (46.4)	7 (9.5)
Grade III	177 (65.8)	92 (34.2)
Grade IV	46 (25.8)	7 (7.6)
Grade V	3 (1.7)	0 (0)
Grade V	3 (1.7)	0 (0)

PFS p=0.733, OS p=0.556

To investigate whether neoadjuvant chemotherapy followed by interval debulking surgery is superior to primary debulking surgery in terms of post-op complications and survival, in advanced epithelial ovarian with high tumor load

NACT and PDS have the same efficacy, when used at their maximal possibilities, but come with different toxicities

@IJGOnline

#IJGCclub If you haven't had a chance to download our lead article by @AinhoaMada please click this link for free access [ow.ly/4w1P50AAqR6](https://ow.ly/4w1P50AAqR6)

@ESGO @IGCSociety @GynMe4 @pedroramirezMD #Oncology #Gynecology #GynOnc #Ovarian #Cancer

Original research

Editorials

Joint statement

Society statement

Meeting summary

Review articles

Consensus statement

Clinical trial

Case study

Video articles

Educational video



Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment... Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have transformed

COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer

Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium

Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice

**SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer**

Luis Chiva, Vanna Zanagnolo, Denis Querleu, Nerea Martín-Calvo, Juan Arvelo-Serrano, Mihai Emil Ciptina, Anna Fagotti, Ali Kuzukmetin, Constantine Mouton, Galina Chakalova, Shamistan Aliyev, Mario Malzoni, Fabrice Narducci, Octavio Arenocibia, Francesco Raspagliesi, Tayfun Toptas, David Cibula, Diyara Kaidarova, Mehmet Kutlu Meydanli, Mariana Tavares, Dmytro Golub, Anna Myriam Parone, Robert Poka, Dimitrios Tsololidis, Goran Vujic, Marcin A Jedryka, Petra L M Zusterzeel, Joghchem Jan Beltman, Frederic Goffin, Dimitrios Haidopoulos, Herman Haller, Robert Jauch, Iryna Yezhova, Igor Barke, Margarida Bernardino, Rashi Bharathan, Maximilian Lanner, Minna M Mastrapasqua, Vachylar Sukhin, Jean-Guillaume Ferron, Robert Frusca, Kersti Kukk, Jordi Ponce, Jose Angel Minguez, Daniel Vázquez-Vicente, Enrique Chacon, Juan Luis Alcázar, et al., On behalf of the SUCCOR study Group

**HIGHLIGHTS**

- Minimally invasive surgery in patients with FIGO 2009 stage IB1 cervical cancer increased the risk of relapse and death
- Patients that underwent minimally invasive surgery using a uterine manipulator had a 2.76-times higher hazard of relapse.
- Avoiding uterine manipulator and implementing a protective vaginal closure was associated with disease-free survival similar to that of open surgery.

**ABSTRACT**

**Background** Minimally invasive surgery in cervical cancer has demonstrated in recent publications worse outcomes than open surgery. The primary objective of the SUCCOR study, a European, multicenter, retrospective, observational cohort study was to evaluate disease-free survival in patients with stage IB1 (FIGO 2009) cervical cancer undergoing open vs minimally invasive radical hysterectomy. As a secondary objective, we aimed to investigate the association between protective surgical maneuvers and the risk of relapse.

**Methods** We obtained data from 1727 patients that underwent a radical hysterectomy by open or minimally invasive surgery. The primary endpoint was disease-free survival (DFS). DFS was defined as the time from random assignment to surgery to the first occurrence of relapse, death, or second primary cancer. DFS was compared between the two groups using multivariable logistic regression. DFS was also compared between patients who underwent minimally invasive surgery with and without a uterine manipulator and between patients who underwent minimally invasive surgery with and without a protective vaginal closure. DFS was also compared between patients who underwent minimally invasive surgery with and without a uterine manipulator and between patients who underwent minimally invasive surgery with and without a protective vaginal closure. DFS was also compared between patients who underwent minimally invasive surgery with and without a uterine manipulator and between patients who underwent minimally invasive surgery with and without a protective vaginal closure.

**FOLLOW THE JOURNAL ON**

Facebook


Twitter

Fellows

Twitter Journal Club

Hashtag #IJGCclub

# Guidelines



**Chair:** Christina Fotopoulou



---

## **Committee:**

---

Elzbieta van der Steen-Banasik

Pawel Knapp

Artem Stepanyan

Nadeem Abu-Rustum

Philipp Harter

ESGO's commitment to research, excellence in care, and education come together with the ESGO Guidelines and Quality Indicators for various gynaecological cancers in order to audit and improve the standard of clinical practice in Europe.

The ESGO Guidelines Committee quickly adapted to the new way of working in 2020 by making the early decision to change most of its in-person meetings to an online-only or hybrid format. In-person meetings were curtailed, and only kept in that format when the members felt that the scientific discussions would benefit from the additional intimacy and longer length of sessions possible when face-to-face.

In 2020, the ESGO Guidelines committee released the **ESGO-ESTRO-ESP Endometrial Cancer Guidelines**. This is a collaboration with the European Society for Radiotherapy and Oncology and the European Society of Pathology. It was first presented at the ESGO 2020 Virtual Meeting in December with publication of unique articles following in the *International Journal of Gynecological Cancer*, *Radiation Oncology*, and *Virchows Archive*. **ESGO President-Elect Nicole Concin** chaired the guidelines project together with **Prof. Carien Creutzberg** from ESTRO and **Prof. Xavier Matias-Guiu**, from ESP.



## **Other 2020 projects included:**


---

- Updated **Quality Indicators for Advanced Ovarian Cancer Surgery**. The update includes new minimum requirements for centres.
- The **ESGO-SIOPe Guidelines for the Management of Adolescents and Young Adults with Non-Epithelial Ovarian Cancers** were published in *Lancet Oncology* in July 2020. This project is with the European Society for Paediatric Oncology and covers patients aged 15 to 25 with these rare tumours, including malignant ovarian germ cell tumours, sex cord-stromal tumours, and small cell carcinoma of the ovary of hypercalcaemic type.

## Algorithms App

The **ESGO Gynae-Cancers Algorithms App** has been an in-the-pocket decision-making resource for medical professionals since 2018. Since it debuted, the App has had more than 8,000 downloads and serves thousands of active users daily. In 2020, ESGO launched the ESGO Algorithms for Rare Gynaecological Tumours Management with GCIG on the app. The algorithm app reflects a consensus recommendation covering the first five key cancer types that were presented at the 21<sup>st</sup> ESGO Congress in November 2019 in Athens, Greece.

The initial five tumour types include low-grade serous, clear cell and mucinous carcinomas of the ovary, ovarian sex cord and germ cell tumours of the ovary.



## ESGO Pocket Guidelines & translations

The Pocket Guidelines are a small-format printable resource for doctors to reference the published ESGO Guidelines easily in their daily practice. Translations of the English-language guidelines are available in Russian, Italian, Spanish, Turkish, French, Portuguese, Arabic, Greek and Serbian. They are available on the Algorithms App as well as on the [guidelines.esgo.org](https://guidelines.esgo.org) and [esgo.org](https://esgo.org) websites.

## **Award!** Cervical Cancer Quality Indicators takes Editors' Choice Award

An article by David Cibula et al. on the ESGO Quality Indicators for Cervical Cancer was given the 2020 Editors' Choice Award by the *International Journal of Gynecological Cancer*.

**Chair:**

Mansoor Raza Mirza (starting October 2020), Antonio González Martín (until October 2020)



**Operational Chair:**

Maren Keller

The European Network of Gynaecological Trial Groups aims to bring the best treatment to gynaecological cancer patients through the best science and enable every patient in every European country to access a clinical trial.

Acting as a research network under the ESGO umbrella, ENGOT has grown to 21 trial groups from 25 countries that perform cooperative clinical studies together.

In 2020, ENGOT moved swiftly to address the unique problems posed to clinical trials by the COVID-19 outbreak, releasing the *Recommendations for clinical trials during the pandemic*

ENGOT was able to hold both of its general assembly meetings in 2020 virtually, ensuring that the network's clinical trial projects and planning were as uninterrupted as possible.

## Cooperation with ENGAGe

ENGOT is working with the ESGO patient advocacy network, ENGAGe (see page 32), on a collaborative clinical trial project that helps educate patients via patient advocacy groups around Europe about clinical trial concepts and how patients can get involved, with the dual goal of increasing participation in clinical trials as well as integrating patient perspectives into clinical trial design. A series of webinars for patients is being planned in 2021.

## Model D

In 2020, the first paper describing ENGOT's new model for clinical trials, "Model D" was published. "Model D allows the performance of several Phase I/II clinical trials with one or more industry partners and multiple ENGOT groups within an integrated programme."

**Read more:** Concin N et al. European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development. *Int J Gynecol Cancer*. 2020 Jun;30(6):730-734. doi: 10.1136/ijgc-2020-001464. Epub 2020 May 12. PMID: 32404377.

## Practice-changing publications

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, ENGOT-ov16/NSGO/NOVA, by Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, et al. and published in *The New England Journal of Medicine*.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer, ENGOT-ov26/GEICO/1509—PRIMA study, by Antonio González-Martín, Bhavana Pothuri, Ignace Vergote et al. and published in *The New England Journal of Medicine*.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer, ENGOT-ov25/GINECO/Paola-1, by Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata et al. and published in *The New England Journal of Medicine*.



## Selected trials closing in 2020

---

- **ENGOT-ov5/MaNGO/INOVATYON**

**Leading group:** MaNGO

**Clinical Trial Study:** Phase III multicentre, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

**Publication:** ESMO 2020

- **ENGOT-ov20/AGO-OVAR OP.4/Desktop 3**

**Leading group:** AGO

**Clinical Trial Study:** Randomised trial investigating secondary debulking versus no-secondary debulking in platin sensitive disease

**Publication:** ASCO 2020

- **ENGOT-ov29/GINECO/ATALANTE**

**Leading group:** GINECO

**Clinical Trial Study:** Randomized trial comparing atezolizumab versus placebo in patients with 1<sup>st</sup> or 2<sup>nd</sup> platinum-sensitive relapse of OC treated with carboplatin combination + bevacizumab

**Publication:** TBA

- **ENGOT-ov39/MITO/IMaGYN 050**

**Leading group:** MITO

**Clinical Trial Study:** A phase III, multicentre, randomized, study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed Stage III or Stage IV ovarian, fallopian tube, or primary peritoneal cancer

**Publication:** TBA



## ENYGO Executive Group 2019–2021

**President:** Andrei Pletnev, Belarus

**Vice President:** Maxmilian Lanner, Austria

**Past President:** Kamil Zalewski, Poland

**Members at large:** Nicolò Bizzarri, Italy; Tanja Nikolova, Macedonia / Germany;  
Zoia Razumova, Sweden; Ilker Selcuk, Turkey; Charalampos Theofanakis, Greece

The events of 2020 have shown more than ever how important it is to have good professional networks in place for learning, best-practice-sharing, and strengthening professional relationships.

**The European Network of Young Gynae Oncologists, ENYGO, is the ESGO network for trainees and medical professionals aged 40 and younger. ENYGO furthers the needs and aspirations of the trainees involved in the study, prevention and treatment of gynaecological cancers and is committed to improving education and training in gynaecological oncology across Europe. In addition, the network serves as a forum for promoting scientific and social interaction, discussion and debate and the exchange of ideas and views.**

In addition to taking an active role by including young doctors in ESGO projects, ENYGO has its own initiatives.

## **LiFE report**

**Editors:** Kristina Lindemann, Zoia Razumova, Kamil Zalewski, Michael Halaska

Now in its twelfth edition, every half year the Literature for ENYGO (LiFE) project produces a report containing summaries of recently published papers relevant to the gynaecological oncology subspecialty. The report is published as a supplement to the International Journal of Gynaecological Cancer and is also available to download free of charge on [enyo.esgo.org](http://enyo.esgo.org). The editors and contributors to the report are all ENYGO members.



## Surveys

---

In 2020, ENYGO conducted several online surveys. Results to be announced.

- **Quality of training in cervical cancer surgery.** The objective of this survey is to make a real-life picture of the training in cervical cancer surgery across Europe and assess whether there has been a change in the training on cervical cancer surgery after LACC trial publication.
- **Attitudes towards sexual counselling of patients with gynaecological malignancies.** This survey aims to examine various aspects of sexual counselling in gynaecological oncology.
- **Gender related-differences among gynaecologic oncology surgeons.** There is evidence that women they are under-represented in leadership positions in the field. The survey aims to find out if there are any specific occupational or specialty-related factors which might influence gender disparities in fellow's professional career.
- **Assessment of palliative care training in GynOnc:** a survey amongst ENYGO members
- **Survey on the impact of COVID19 on gynaecological oncology trainees.**



## Webinars

---

ENYGO produces several monthly webinars specifically for gynae-oncologists and other interested professionals at the beginning of their careers. The key objective of the webinars is to create an interactive environment between the fellows and international experts.

All webinars are free to join and are available afterward on the ESGO eAcademy.

### **English-language webinars**

---

- Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer - Results of NRG Oncology/Gynecologic Oncology Group study GOG-0213: a multicentre, open-label, randomised, phase 3 trial, January, **Robert L Coleman**
- ENYGO LiFE Report—10th edition, February 26, **Kristina Lindemann and Zoia Razumova**
- How to select patients for PDS in advanced ovarian cancer, March 19, **Anna Fagotti**
- Enhanced Recovery After Surgery- New Standard of Care in Surgery, April 8, **Pedro Ramirez**
- Managing PARP inhibitors in recurrent ovarian cancer- the new norm, May 20, **Jonathan Ledermann**
- Principles of colorectal resection and anastomosis in cytoreductive surgery, June 17, **Luis Chiva**

- Individualized surgical and medical therapy in gynaecological sarcoma, how to communicate with patients, July 29, **Jalid Sehouli**
- DESKTOP III Trial Results: Do patients in recurrent ovarian cancer benefit from cytoreductive surgery?, August 12, **Andreas du Bois**
- ENYGO LiFE Report, September 23, **Zoia Razumova**
- Immunotherapy in gynaecologic oncology, October 28, **Christian Marth**
- Integrating tumour biology into debulking surgery, November 25, **Nicole Concin**
- Integrating PARPi in front line of advanced ovarian cancer, December 9, **Antonio González Martín**

## **Russian-language webinars**

## **NEW in 2020!**

- ENYGO's Russian-language webinars were started in 2020 by ESGO Council Member Artem Stepanyan (Armenia) to address the need for instruction in the subspecialty for young doctors in Russian-speaking countries. The webinars are moderated by ENYGO National Representative, **Archil Sharashenidze (Georgia)**
- Ovarian cancer cytoreductive surgery: How I do it, March 3, **Artem Stepanyan**
- Modern molecular oncology to oncogynecology: from fundamental theories to clinical practice, April 30, **Natalia Volodko**
- Surgical treatment of cervical cancer: Modalities of cervical cancer treatment in the Russian Federation, May 23, **Ulrikh Elena & Igor Berlov**
- The role of systemic chemotherapy in the treatment of locally advanced cervical cancer, June 6, **Iga Matylevich**
- Pre- and postoperative evaluation, morbidity and postoperative outcome of elderly cancer patients, July 30, **Dina Kurdiani**
- Laparoscopic Pelvic Exenteration: Our experience and technique, October 31, **Sergey Baido**
- Laparoscopically assisted radical vaginal hysterectomy (Shauta operation), December 17, **Irakli Todua**

## Masterclass in Gynaecological Oncology

ENYGO holds an annual Masterclass in Gynaecological Oncology that covers the entire subspecialty. Unfortunately, the 2020 Masterclass was cancelled due to the COVID-19 pandemic. ENYGO looks forward to holding a great event—safely—in Rome, June 24–26 2021.



## NEW PROJECT in 2021

Scientific Writing and Publication online course in collaboration with the International Journal of Gynecological Cancers. Registration opens Jan 29, 2021.

**FOLLOW ENYGO  
on social media!**

Facebook  
Twitter  
[enygo.esgo.org](http://enygo.esgo.org)

## ENGAGe Executive Group

**Co-chairs:** Murat Gultekin and Icó Tóth



**Past Co-chair:** Esra Urkmez

Birthe Lemley, Maria Papageorgiou, Karina Dahl Steffensen, Kamil Zalewski, Maja Pakiz, Petra Adamkova, Kim Hulscher

## About ENGAGe

**ENGAGe is the voice of gynaecologic cancer patients in Europe.**

Established in 2012 by ESGO, the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) represents advocacy groups of patients affected by all types of gynaecologic cancers, from the rarest to the most common, in particular: ovarian, endometrial, cervical, vulvar and rare cancers. It has over 68 gynaecologic cancer advocacy group members from 28 countries.

Following eight years of growth in the prevention and advocacy spheres, the ENGAGe Executive Group met in Budapest in February 2020 to redefine the network's mission, vision, and tagline:

### ENGAGe vision

Prevention of  
gynaecological cancers  
and access to the best  
treatment.

### ENGAGe mission

To empower a patient-centric  
approach to gynaecological  
cancer care, research and prevention  
through awareness,  
advocacy and education.

ENGAGe is growing. In 2020, we gained ten new members. Unlike in years past, due to a recent bylaw change, our new members include members associations, individual members, and associate members. To keep up with our growing organisation, there are four newly established EN-  
GAGe patient committees, one for each common gynae cancer type whose members collaborate on ENGAGe projects.



## ENGAGE 2020 Projects

---

### • COVID-19 Survey

In response to the COVID-19 pandemic, ENGAGE member organisations and ESGO clinicians collaborated to **survey gynaecological cancer patients** in Europe about their attitudes and experiences while seeking treatment during the pandemic. In all, 1,388 responses were collected and the results were published as the paper “Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGE)” by Gultekin et al. in the November edition of the journal *Cancer Medicine*. The results can also be read on the ENGAGE website. A follow-up survey is being planned for 2021.

### • COVID-19 Webinar

Drawing on the results of the COVID-19 patient survey, as well as the results of the ESGO-ENGOT survey on changes in patient care across Europe, ENGAGE held a webinar on patient perspectives on September 8 for the professional healthcare community. A recording of the webinar can be viewed on the ESGO eAcademy.

**Moderator:** Maximilian Lanner

**Topics:**

- Patient perspectives during the pandemic (Murat Gultekin, Icó Tóth)
- Doctors’ perspectives and experiences during the pandemic (Sara Nasser)
- How to re-organise medically (Anna Fagotti, Nicoletta Colombo)
- Communication during and after the pandemic (Jalid Sehouli)

A panel discussion followed, moderated by Fagotti and Sehouli and including panellists Colombo, Tóth, and ESGO President Philippe Morice.

### • Patient Webinars and Brochures

ENGAGE projects address the needs of patients and also of patient advocacy groups.

Periodically in 2020, ENGAGE produced webinars for members to help patient advocates share best practices between the different countries where member organisations are located.

More directly for patients, in 2020, ENGAGE published four brochures explaining clinical topics in simple language; these brochures are then translated into member groups’ languages. As of publication, ENGAGE has produced 75 brochures translated into 21 languages.

**2020 new brochures:**

- What you should ask the doctor
- Radiotherapy
- Lymphoedema
- Clinical trials

## • Patient Focus Groups

In 2020, as part of its work to amplify the voices of patients, ENGAGe facilitated seven 1.5-hour-long virtual roundtable discussions between patients and pharmaceutical company representatives.

## • Patient Advocacy Week, November 30–December 5, 2020

ENGAGe brings together delegates from its member groups annually for Patient Advocacy Seminars that foster knowledge sharing between patients and doctors as well as between the member advocacy groups themselves. Due to the pandemic, this year's event was changed to a week-long online-only series of Facebook events in which patients shared their stories, webinars and virtual classes in which clinicians educate patient advocates, and social events such as cooking and photography classes.

### This year, highlights included:

- A presentation on cervical cancer—challenges and opportunities for Eastern Europe—with Murat Gultekin and special guest Dr Princess Nothemba Simelele from the World Health Organization
- A discussion of rare cancers with Nicholas Reed
- A discussion on palliative care in various locations with Karina Dahl Steffensen, Annete Hasenburg, Kamil Zalewski and Maja Pakiz

See page 26 to learn about ENGAGe's  
Clinical Trial project with ENGOT.

Follow ENGAGe

Facebook

YouTube

Website



## PROGRAMME

### Monday 30/11

- |  |   |
|--|---|
| <p>① <b>10 a.m. CET Patient doctor communication - importance of patient advocacy groups</b><br/>Ico Toth, Sara Nasser (Storytelling on FB page)</p> | <p>② <b>2 p.m. CET What should I ask when I find out I have a cancer</b><br/>Kim Hulscher (Best practice sharing on FB group)</p> |
|--|---|

### Tuesday 1/12

- |  |   |
|--|---|
| <p>① <b>10 a.m. CET Rare cancer</b><br/>Eva-Maria Stromsholm (Storytelling on FB page)</p> | <p>② <b>2 p.m. CET GO Day all over the world</b><br/>Petra Adámková (Best practice sharing on FB group)</p> |
|--|---|

### Wednesday 2/12

- |   |  |
|---|--|
| <p>① <b>10 a.m. CET Endometrial cancer</b><br/>Maaïke (Olijf) (Storytelling on FB page)</p> | <p>② <b>2 p.m. CET „How can I live now“ initiative from Ukraine</b><br/>Natalya Khandobina (Best practice sharing on FB)</p> |
|---|--|

### Thursday 3/12

- |   |  |
|---|--|
| <p>① <b>10 a.m. CET Cervical cancer</b><br/>Anne De Middelaer (Storytelling on FB page)</p>   | <p>⑤ <b>6-6:30 p.m. CET PARP-inhibitors: patients ask and doctors answer</b><br/>Jonathan Ledermann (Webinar)</p>  |
| <p>② <b>2 p.m. CET Sweden free of cervical cancers in 5 years</b><br/>Barbro Sjolander (Best practice sharing on FB group)</p>              | <p>⑥ <b>6:30-7:00 p.m. CET Patient Associations' role during the Covid-19 pandemic</b><br/>Ic6 T6th, Kim Hulscher, Murat Gultekin (Webinar)</p>  |
| <p>③ <b>5-5:15 p.m. CET PAW Welcome word</b><br/>Philippe Morice, Ico Toth, Murat Gultekin (Webinar)</p>                                    | <p>⑦ <b>7:10-7:40 p.m. CET Cervical cancer - the preventable disease - Today's tools and possibilities, challenges and opportunities for Eastern Europe</b><br/>Murat Gultekin, Princess Nothemba Simelela (WHO) (Webinar)</p> |
| <p>④ <b>5:15-5:45 p.m. CET Endometrial Cancer: early or late, advancements in tools and possibilities</b><br/>Philippe Morice (Webinar)</p> |  |

### Friday 4/12

- |  |   |
|--|---|
| <p>① <b>10 a.m. CET Ovarian cancer</b><br/>Malgorzata Kretowska (Storytelling on FB page)</p>  | <p>④ <b>5:15-5:45 p.m. CET Clinical Trials Project: How far are we?</b><br/>Birthe Lemley, Jalid Sehoul (Webinar)</p> |
| <p>② <b>2 p.m. CET Rehabilitation/ quality of life</b><br/>Ico Toth (Best practice sharing on FB group)</p>  | <p>⑤ <b>5:45-6:15 p.m. CET We rarely hear about rares</b><br/>Nicholas Reed (Webinar)</p>                             |
| <p>③ <b>4-5 p.m. CET Palliative care: mapping the situation in diverse countries</b><br/>Karina Dahl Steffensen, Annette Hasenburg, Kamil Zalewski, Maja Pakiz (Virtual classroom)</p> | <p>⑥ <b>6:30-7 p.m. CET Is the ovarian cancer really an ovarian cancer?</b><br/>Ranjit Manchanda (Webinar)</p>        |

### Saturday 5/12

- |  |  |
|--|--|
| <p>① <b>10-10:45 CET Integrative medicine</b><br/>Jeanett Kertevig (Webinar)</p> | <p>② <b>10:45-12:00 CET General Assembly</b></p> |
|--|--|

### SOCIAL PROGRAMME

1:00-3:00 p.m. CET Emotional photography • 3:15-3:45 p.m. CET Line dance • 4:00-5:00 p.m. CET Yoga class  
5:30-6:30 p.m. CET Cooking class • 6:30-7:30 p.m. CET Final toast



# World Gynaecological Oncology Day

## World GO Day activities

took place in 25 countries: Austria, Belarus, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, India, Ireland, Italy, Kazakhstan, Poland, Romania, Serbia, Spain, Sweden, Turkey, Ukraine, USA.


World Gynaecological Oncology Day was observed around the world on September 20, 2020.

- Second annual event
- reached 6.4M people with the #GoForPurple campaign on social media directly
- reached another 5M+ audience via media worldwide

***“We want people to know that having a regular check-up with your gynaecologist should be a priority,”*** – Icó Tóth, ENGAGe Co-Chair and a patient advocate.

Through social media campaigns, World GO Day shared educational information about the main types of gynaecological cancers: cervical, ovarian, uterine, vaginal, and vulvar.

Because of the pandemic, most local organisers switched from in-person to online social and awareness activities, such as recording videos for social media and using a frame for Facebook profile pictures. **This year, the campaigns from the more than 60 partners focused on HPV prevention and disease symptoms. In addition, selected landmarks around the world were illuminated with purple lights to promote the #GOforPurple campaign.**



Participant videos are available to watch on the World GO Day YouTube channel.

Follow World GO Day at

Instagram  
Facebook  
Twitter  
YouTube  
Website



# Prevention activities

## Prevention & Advocacy Committee

**Chair:** Murat Gultekin



**Prevention Working Group:** Maria Kyrgiou, Marc Arbyn, Elmar Joura, Jalid Sehoul

**Advocacy & awareness Working Group:** Icò Tòth, Pawel Knapp, Jalid Sehoul, Maja Pakiz

**Excellence in cancer care is great. Prevention of the need for that care in the first place is better.**

ESGO is proud to take part in several local, regional and international initiatives for cancer prevention, through our Prevention and Advocacy Committee and ESGO ENGAGe, our patient advocacy group network. In 2020, several exciting new projects, publications and cooperations came to fruition:

## Publications

- **Consensus Statement:** ESGO-EFC position paper of the European Society of Gynaecological Oncology and the European Federation of Colposcopy (EFC) on cervical screening, Kyrgiou, et al. published in the *British Journal of Cancer* June 2020.
- **Letter:** "Tackling cervical cancer in Europe amidst the COVID-19 pandemic" signed by Arbyn et al. published in *The Lancet*, August 2020.
- **Paper:** The European Response to the WHO call to eliminate cervical cancer as a public health problem, Arbyn et al. published in the *International Journal of Cancer*, June 2020

## World Health Organization initiative to eliminate cervical cancer

ENGAGe co-Chairs Murat Gultekin and Icò Tóth, along with ENGAGe Executive Group member and patient advocate Kim Hulscher have led ESGO cooperation with the World Health Organization's global strategy to eliminate cervical cancer! As part of this, Dr. Princess Nothemba Simelela, Special Adviser to the Director-General on Strategic Programmatic Initiatives at WHO presented on cervical cancer elimination during the ENGAGe Patient Advocacy Week in December. On November 17, patient advocates Toth and Hulscher presented during the WHO cervical cancer elimination launch programme and provided their storytelling videos about their experiences with cervical cancer.

## EU-funded RISCC Project

**RISCC stands for "Risk-based Screening for Cervical Cancer".** Cervical cancer is a preventable disease caused by HPV. There are several other risk causes, such as tobacco use, use of oral contraceptives and impaired immune system (HIV infections, organ transplantation or autoimmune diseases). Among infected women, only a few women will develop cancer. But how do we know who it will be? The EU-funded RISCC project will study these factors to estimate the individual risk of each woman and provide personalised interventions so that cervical cancer is prevented. ESGO Prevention Committee Chair and ENGAGe Co-chair Murat Gultekin, and ENGAGe Co-chair Icò Tòth are the ESGO representatives on this project.

# Cooperations

## ESGO is a European society with a global outlook.

Part of serving our membership is reaching out to their other affiliations and finding ways to build bridges and synergies both near and far. In addition to the collaborations with ESTRO, ESP, SIOPe, GICG and more mentioned in the Guidelines section of this Update (page 24), the cooperations with the World Health Organisation, the RISCC project and others mentioned under Prevention (page 38), the collaboration with IGCS to publish the *International Journal of Gynecological Cancer*, and the many, many partnerships between many clinical trial groups and patient advocacy groups brought together by ENGOT and ENGAGE, ESGO has built links to several other organisations in 2020 and we would like to recognise all of those relationships here.



### Dual membership with ESTRO

In 2021, ESGO and ESTRO began to offer a dual membership plan, whereby members of one organisation can get membership to the second organisation at a special price.



### ENGAGE-World Ovarian Cancer Coalition cooperation

The founders of World Ovarian Cancer Day and ENGAGE have formalised their cooperation this year.



### ESO cooperation on the ENYGO Masterclass in GO

This long-standing cooperation helps give our young doctors a full overview of the subspecialty at one great event. We are looking forward to the 2021 Masterclass!



### National societies

ESGO works to maintain links with national and regional societies in order to improve the sharing of knowledge and cooperation in our field throughout Europe and the world.



### Courses with ESGE, SERGS and more!

Our roster of courses and other educational events are stronger and the participants' experiences better because of our partnerships in developing and delivering practical workshops and other courses.

# Membership



## Membership Committee



**Chair:** Nicole Concin

**Industry:** Antonio González Martín, Mansoor Mirza

**Patient Advocates:** Murat Gultekin, Icò Tòth

**Institutional (national and sister societies):**

Denis Querleu, Elzbieta van der Steen-Banasik

**Individual:** Artem Stepanyan,

Nadeem Abu-Rustum, Zoia Razumova (ENYGO),

Susana Banerjee (ESMO), Jalid Sehouli,

Denis Querleu, Elzbieta van der Steen-Banasik

Our success as a Society as defined by our membership. Our members report themselves as specialists in epidemiology, gynaecology/obstetrics, gynaecologic oncology, medical oncology, molecular biology, pathology, radiation oncology, radiology, nursing and more!

We'd like also to extend a warm thank you to the ESGO Advocates, the generous individuals who elected to give a donation to us in addition to their membership fees. The amount collected will help subsidise our educational efforts, particularly those aimed at fellows and low-resource areas.

## Members 2020

by the numbers


More than **2300** ...  
...at time of printing  
from **117** countries

## Big 5

with most members

UK  
Spain  
India  
Italy  
Germany

Our 250+ trainee members are eligible to participate in the European Network of Young Gynae Oncologists, ENYGO. To learn more about ENYGO's activities [see page 28](#)



## ESGO membership benefits include:

### Reduced prices

- ESGO 2021 Hybrid-format Congress in Prague\*
- ESGO Courses\*
- ESGO Exam


### Free access

- International Journal of Gynecological Oncology & IJGC eTOCs
- ESGO eAcademy\*
- ESGO monthly webinars

### Opportunities to grow

- Traveling Fellowship
- Short Clinical Visits
- ENYGO webinars & workshops for young professionals\*
- Endorsed meetings in your region
- ESGO networks & task forces

\*CME credits



**To join ESGO  
or renew  
your membership,  
go to [esgo.org](http://esgo.org)**

# ESGO Elected Officials

## Executive Board



### Officers:

**President:** Philippe Morice (France)

**President Elect-Treasurer:** Nicole Concin (Austria)

**Vice President:** Jonathan Ledermann (UK)

**Past President:** Denis Querleu (France)

**Executive Director (Ex Officio):** Renata Brandtnerova (Czech Republic)

## MEMBERS OF THE COUNCIL

### 12 elected members

Anna Fagotti (Italy)

Christina Fotopoulou (UK)

Mansoor Raza Mirza (Denmark)

Pawel Knapp (Poland)

Cagatay Taskiran (Turkey)

Elzbieta Banasik-van der Steen (Netherlands, Romania)

Maja Pakiz (Slovenia)

Jalid Sehoul (Germany)

Jan Persson (Sweden)

Luis Chiva (Spain)

Artem Stepanyan (Armenia)

Ignacio Zapardiel (Spain)

### 4 appointed members

**International Council Member:** Nadeem Abu-Rustum (USA)

**Representatives of ENGOT:** Antonio González Martín (Spain)

**ENYGO:** Andrei Pletnev (Belarus)

**ENGAGE:** Murat Gultekin (Turkey) and Içò Tòth (Hungary)



# ESGO Council 2019-2021



## ESGO Office



**Renata Brandtnerova**  
*Executive Director*

**Michaela Cidlinova**  
*Senior education manager*

**Lucie Lamlova**  
*Senior communication and marketing manager*

**Zuzana Seps**  
*Executive congress manager*

**Eva Streglova**  
*Senior project manager & ENGAGe coordinator*

**Eva Beranova**  
*Project Manager & ENGOT coordinator*

**Tereza Cicakova**  
*Membership & ENYGO Coordinator*

**Beth Green**  
*Communications*

**Andrea Hokrova**  
*Financial manager*

**Jana Holanova**  
*Project manager*

**Kamila Macku**  
*Project coordinator*

**Helena Opolecka**  
*Project manager*

# What's to come in 2021

One of the key messages of our 2020 State of the Art Virtual Meeting, which was a milestone in the history of ESGO, is the incredible level of expectations and the wish to “gather and share together” within our community. We are thirsty for high-quality scientific meetings with great interactivity, and that is exactly the need we are preparing to meet at **the ESGO 2021 Congress in Prague**.

Our educational courses are also vitally important this year. We are reactivating old ones greatly valued before COVID and bringing in new ones, such as courses on **molecular pathology** and targeted therapy, **bowel surgery** and advanced procedures for gynae-oncologists, and the **advanced course on the surgery of cervical cancer**. The target is, depending on the state of health of the continent, to (re)open some of these courses in 2021.

Our three networks (ENYGO, ENGAGe, and ENGOT) are the apples of our eyes. They boost the stature of ESGO and also help us look to the future. They are planning many exciting new activities for you this year.

**Prevention** is a new and particularly challenging area that was tackled for the first time last year. Great progress has been made in the development of scientific publications. Multiple projects shall be finalised in 2021.

Concerning the guidelines, new topics will be covered in 2021, such as **peri-operative management in ovarian cancer**, **pre-operative diagnosis in ovarian tumours**, and a new guideline integrating ESTRO and SIOPe experts' views about the management of vaginal cancer. A consensus conference will be organized in 2022 under the ESMO and ESGO umbrella to work on ovarian cancer management. Groups are working on **quality indicators on endometrial cancer surgery**, on **radiation therapy treatment in cervical cancer** (with ESTRO colleagues), and updates of vulvar and cervical cancer guidelines will be open. We are also progressing the processes through the accreditation and certification committee to define **ESGO centres for cervical cancer treatment** in the near future.

In this context, where face-to-face meetings with officers from other societies are not possible, special links and contacts are crucial in maintaining **very strong connections** across scientific and educational projects, particularly with colleagues and friends from IGCS, ESTRO, ESMO, ESO, ESGE, ESHRE, and SERGS.

This is just a brief overview of what is on our plate for 2021. We will continue to **improve the visibility of ESGO in and outside Europe, and, above all, to improve the quality of the treatment of patients with gynaecological cancers** because this remains our primary *raison d'être*.

*Philippe Morice*  
*President*

*Jonathan Ledermann*  
*Vice President ESGO*



# 22<sup>nd</sup> European Congress on Gynaecological Oncology

October 23-25, Prague, Czech Republic



PRAGUE, CZECH REPUBLIC

2021

[congress.esgo.org](http://congress.esgo.org)



The European Voice of Gynaecological Oncology



---

## More information about ESGO:

---

Webpage: [esgo.org](http://esgo.org)

Email: [adminoffice@esgo.org](mailto:adminoffice@esgo.org)

Facebook: [@EuropeanSocietyofGynaecologicalOncology](https://www.facebook.com/EuropeanSocietyofGynaecologicalOncology)